Affiliation:
1. Ludwig-Maximilians-Universitat Munchen Medizinische Fakultat
2. DZNE-Standort München: Deutsches Zentrum fur Neurodegenerative Erkrankungen Standort Munchen
3. Ludwig-Maximilians-Universitat Munchen Biomedizinisches Centrum Munchen
4. Ludwig-Maximilians-Universität München Strahlenbiologisches Institute: Ludwig-Maximilians-Universitat Munchen Medizinische Fakultat
5. Ludwig-Maximilians-Universität München: Ludwig-Maximilians-Universitat Munchen
Abstract
Abstract
The constitutive photomorphogenesis 9 (COP9) signalosome (CSN) is a deNEDDylase controlling ubiquitination activity of cullin-RING-E3 ligases (CRLs) and thus the levels of key cellular proteins. While the CSN and its catalytic subunit CSN5 have been extensively studied in cancer, its role in inflammatory and neurological diseases is less understood. Following verification that CSN5 is expressed in mouse and human brain, here we studied the role of the CSN in neuroinflammation and ischemic neuronal damage employing models of relevant brain-resident cell types, an ex vivo organotypic brain slice culture model, and the CRL NEDDylation state-modifying drugs MLN4924 and CSN5i-3, which mimic and inhibit, respectively, CSN5 deNEDDylase activity. Unbiased mass spectrometry-based proteomics revealed that MLN4924 and CSN5i-3 substantially alter the microglial proteome, including inflammation-related proteins. Applying these drugs, mimicking microglial and endothelial inflammation as well as ischemic neuronal stress by TNF-α and oxygen-glucose-deprivation/reoxygenation (OGD/RO) treatment, we could link CSN5/CSN-mediated cullin deNEDDylation to reduction of microglial inflammation, attenuated cerebral endothelial inflammation, improved barrier integrity, as well as protection from ischemia stress-induced neuronal cell death. Specifically, MLN4924 reduced phagocytic activity, motility, and inflammatory cytokine expression of BV2 and primary microglial cells, and this was linked to inhibition of inflammation-induced NF-kB, MAPK, and Akt signaling. Inversely, Csn5 knockdown and CSN5i-3 increased NF-kB signaling. Moreover, MLN4924 abrogated TNF-a-induced NF-kB and MAPK signaling in cerebral microvascular endothelial cells (hCMECs) and rescued hCMEC monolayers from OGD/RO-triggered barrier leakage via restoring tight junctions, while CSN5i-3 exacerbated permeability. In an ex vivo organotypic brain slice model of ischemia/reperfusion stress, MLN4924 protected from neuronal death, while CSN5i-3 impaired neuronal survival. Neuronal damage was attributable to microglial activation and inflammatory cytokines, as indicated by microglial shape tracking and TNF-a-blocking experiments. Our results indicate a protective role of the CSN in neuroinflammation via several brain-resident cell types involved in ischemic brain disease and implicate CSN activity-mimicking deNEDDylating drugs as potential therapeutics.
Publisher
Research Square Platform LLC